CSL Limited (ASX:CSL) reminded investors today that even Australia’s biggest biotech can bleed. Shares in the $90 billion plasma and vaccine giant plunged more than 15% after the company slashed guidance for FY26 and deferred the long-planned spin-off of its Seqirus vaccines business — a double blow that rattled the entire ASX healthcare sector.
The sell-off erased nearly A$15 billion in market value for CSL, dragging the ASX 200 lower and sending the healthcare index to its weakest point in more than a year, falling more than 7%. For a stock long considered a defensive cornerstone, the magnitude of the move was sobering.
Guidance reset and delayed spin-off
At Tuesday morning’s annual general meeting, CEO Paul McKenzie cut profit growth guidance for FY26 to 4–7%, down from 7–10% flagged in August. Revenue growth is now seen at just 2–3%, roughly half prior expectations. The culprit: sharply lower influenza vaccination rates in the US, CSL’s largest market, which have dented Seqirus earnings and forced a rethink on timing for the division’s demerger.
“Given the heightened volatility in the current US influenza vaccine market, we have concluded that advancing with the previously proposed demerger timing will not fully capture Seqirus’ value potential,” chairman Brian McNamee told shareholders.
CSL now intends to revisit the separation once market conditions stabilise — likely beyond FY26 — but insisted the strategic logic remains intact.
A complex cure for complexity
The AGM followed what had billed as a get-fit year for CSL. The company has been trimming R&D spending, rationalising its product pipeline and restructuring operations to reduce cost and bureaucracy, with plans to cut headcount by up to 15% and a target of $500 million–$550 million in annual savings by FY28.
Read more: CSL profit beats forecasts but market reels from sweeping restructure
Nonetheless, McNamee conceded that “for some time now, CSL has been operating in a way that is too complex”, and pledged faster execution on the simplification agenda.
The sharper-than-expected guidance cut suggests recovery in the vaccines arm will take longer to materialise, while near-term earnings will lean heavily on CSL Behring — its plasma-derived therapies business — and the newer Vifor nephrology portfolio.
Market reaction: Brutal but not surprising
CSL’s shares hit their lowest level since 2019, marking one of the stock’s worst single-day performances on record. Analysts pointed to investor fatigue after several years of underperformance and repeated strategic resets.
The downgrade comes just two months after the company reported 14% growth in FY25 net profit after tax and amortisation (NPATA) to US$3.3 billion and unveiled plans for the Seqirus demerger. That apparent turning point has now given way to what looks like another drawn-out transition period.
Healthcare peers including Ramsay Health Care Limited (ASX:RHC), Resmed Inc (NYSE:RMD) and Sonic Healthcare were caught in the downdraft, though none matched CSL’s dramatic fall. The healthcare sector ended the session among the ASX’s worst performers, underscoring how one heavyweight can drag sentiment across the board.
Trust, governance and timing
The AGM also drew attention to a brewing governance issue, with CSL facing a second strike on executive remuneration. Shareholder unease about pay against a backdrop of declining returns reflects the erosion of confidence in management’s ability to deliver consistent growth.
Despite today’s turmoil, both McNamee and McKenzie stressed CSL’s fundamentals remain strong, with plasma collections growing and a pipeline of next-generation therapies progressing through clinical trials. They reaffirmed expectations for a profit recovery in FY27 and beyond, though much will depend on stabilising the vaccine market in the US — a prospect complicated by waning demand and political scepticism around vaccination.
“Due to ongoing uncertainty in the US influenza market, while there are some scenarios in which group NPATA growth may touch double digits, we believe high single-digit growth is a more appropriate expectation until the US influenza vaccine market improves,” McKenzie said.
To signal confidence, CSL announced a share buyback program starting FY26, even as it braces for restructuring costs. That move may soothe nerves, but execution risk remains high.
Looking ahead
For long-term investors, CSL’s transformation story is not over, but patience will be tested. The market is clearly demanding proof that simplification and capital discipline can translate into renewed earnings momentum.
With healthcare once again underperforming the broader market, CSL’s stumble is a stark reminder: even industry leaders can lose their footing when global health trends shift. Until the company shows its leaner structure can deliver steady growth without vaccine tailwinds, investors may be reluctant to pay a premium for promise alone.